Recruiting

3D-MRE for Assessing Cirrhosis, Advanced Chronic Liver Disease and Portal Hypertension

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.

ClinicalTrials.gov IDNCT05475015

PhaseNot Applicable

Enrollment150

SponsorShengjing Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Cirrhosis, Liver, Portal Hypertension, Advanced Chronic Liver Disease

About this study

Interventions

Device: 3D-MRE — All imaging studies were performed by using a 3.0-T MRI system ( GE Healthcare) with a phasedarray body coil.
Device: HVPG — HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.

Primary outcomes

Accuracy of the features of 3D-MRE for assessing portal hypertension in cirrhosis. (12 months)

Eligibility information

Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior. Exclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.

Study locations

Shengjing Hospital, Shenyang, Liaoning 210000 China

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.